Accuray Competitors

Accuray (NASDAQ:ARAY) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Risk & Volatility

Accuray has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Accuray and Abbott Laboratories' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Accuray and Abbott Laboratories' gross revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

69.8% of Accuray shares are owned by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are owned by institutional investors. 4.0% of Accuray shares are owned by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Accuray and Abbott Laboratories, as reported by MarketBeat.

Accuray currently has a consensus price target of $8.00, suggesting a potential upside of 57.48%. Abbott Laboratories has a consensus price target of $115.6875, suggesting a potential upside of 0.84%. Given Accuray's higher possible upside, equities research analysts plainly believe Accuray is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats Accuray on 10 of the 13 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Medtronic (NYSE:MDT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Accuray and Medtronic's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Accuray and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Medtronic, as provided by MarketBeat.com.

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Medtronic has a consensus price target of $122.2963, indicating a potential upside of 4.62%. Given Accuray's higher probable upside, research analysts clearly believe Accuray is more favorable than Medtronic.

Summary

Medtronic beats Accuray on 12 of the 15 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Stryker (NYSE:SYK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Accuray and Stryker's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Accuray and Stryker's top-line revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 6.8% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Stryker, as provided by MarketBeat.com.

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.04%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Stryker.

Summary

Stryker beats Accuray on 12 of the 15 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Accuray and Intuitive Surgical's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Accuray and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Intuitive Surgical, as provided by MarketBeat.com.

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Intuitive Surgical has a consensus price target of $736.0588, indicating a potential downside of 2.12%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Accuray on 10 of the 14 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Accuray and Becton, Dickinson and's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Accuray and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Becton, Dickinson and has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Becton, Dickinson and, as provided by MarketBeat.com.

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Becton, Dickinson and has a consensus price target of $279.6667, indicating a potential upside of 7.46%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Becton, Dickinson and.

Summary

Becton, Dickinson and beats Accuray on 10 of the 14 factors compared between the two stocks.

Accuray (NASDAQ:ARAY) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Accuray has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares Accuray and Edwards Lifesciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Accuray and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

69.8% of Accuray shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 4.0% of Accuray shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Accuray and Edwards Lifesciences, as provided by MarketBeat.com.

Accuray presently has a consensus price target of $8.00, indicating a potential upside of 57.48%. Edwards Lifesciences has a consensus price target of $90.8704, indicating a potential upside of 5.80%. Given Accuray's stronger consensus rating and higher probable upside, research analysts clearly believe Accuray is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats Accuray on 10 of the 14 factors compared between the two stocks.